Centogene N.V announced that Oved Amitay will be stepping down as Chief Business Officer and leaving the Company effective May 31, 2020. He will be succeeded by Sun Kim, current Chief Strategy and IR Officer, who will assume Mr. Amitay’s responsibilities until a permanent CBO has been appointed. Mr. Amitay will continue his work for rare diseases patients in the non-profit sector, where he will serve as Chief Executive Officer of a patient advocacy organization.

Prior to joining CENTOGENE, Mr. Kim was Head of Corporate Strategy at Shire Plc. Prior to joining Shire Plc, he worked in the Alcon division of Novartis in multiple roles, including General Manager of Singapore and Global Head of Strategy.  Mr. Kim also worked at Bausch & Lomb, leading its strategy function for the pharmaceutical business unit and the global generics franchise. Prior to his experience in the pharmaceutical industry, Mr. Kim spent seven years as a management consultant at McKinsey & Company and A.T. Kearney.

Prof. Arndt Rolfs, CEO of the Company, said, “We want to thank Oved for his significant and important contributions to CENTOGENE´s growing and positioning and wish him well. He has built a strong team and under his leadership, our Pharma business evolved into a major growth driver for the company. Sun’s previous experiences in strategy and commercial operations at leading biotechnology and pharmaceutical companies will be extremely valuable, and I would like to thank him for expanding his role at this time, as we continue to focus on our critical collaborations.”